Immunovant, Inc. Common Stock Earnings Dividend

Immunovant, Inc. Common Stock’s revenue jumped +Inf% since last year same period to $7.1Mn in the Q2 2026. On a quarterly growth basis, Immunovant, Inc. Common Stock has generated +Inf% jump in its revenue since last 3-months.

Immunovant, Inc. Common Stock’s net profit fell -27.04% since last year same period to $-153.22Mn in the Q2 2026. On a quarterly growth basis, Immunovant, Inc. Common Stock has generated -3.63% fall in its net profits since last 3-months.

Immunovant, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -2159.61% in the Q2 2026. On a quarterly growth basis, Immunovant, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Immunovant, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.66 - a -4.76% fall from last quarter’s estimates.

Immunovant, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.66.

Immunovant, Inc. Common Stock’s earning per share (EPS) fell -5.63% since last year same period to -0.75 in the Q2 2026. This indicates that the Immunovant, Inc. Common Stock has generated -5.63% annual rate of fall in its earning per share (EPS) in the last 4 quarters.